Keywords:
Genital / Reproductive system male, CT, Radiation therapy / Oncology, Radiotherapy techniques
Authors:
W. L. Ong, F. Foroudi; VIC/AU
DOI:
10.26044/ranzcr2019/R-0117
Results
A total of 6 studies were included in this review.
Baseline characeristics
- A total of 141 patients were included in this review
- Majority of patients had EBRT (116/141), 2 had EBRT and brachytherapy, and 23 had brachytherapy alone
- The reported median EBRT dose ranged from 73.8Gy to 80Gy.
- The median interval between curative radiotherapy and SBRT reirradiation ranged from 13.5 to 115 months
- 59-100% of patients had biopsy confirmation of LR
- All studies reportd the use of combinatin of magnetic resonance imaging (MRI), and positron emission tomography (PET) for staging to confirm LR with no distant metastasis prior to SBRT
SBRT dose, fractionation and technique
- Five studies used Cyberknife for SBRT, while one reported a mixed of Cyberknife and Linac based approach
- The SBRT dose/ fractionation ranged from 30-36.25 Gy in 5-6 fractions
- The proportion of patients who had concurrent androgen deprivation therapy was 33-61%
Oncological outcomes
- The median follow-up post SBRT ranged from 9.5 to 2.4 months
- The proportion of patients who had PSA decline post SBRT were 60-83%
Toxicity outcomes
- Three studies reported toxicities using the CTCAE criteria, while three used the RTOG scoring
- Acute Grade 2 and Grade 3+ GU toxicities were reported in 5.3-22% and 0-9% of patients
- Acute Grade 2 and Grade 3+ GI tixicities were reproted in 0-11% and 0% of patients
- Late Grade 2 and Grade 3+ GU toxicities were reported in 0-7% and 0-7% of patients
- Late Grade 2 and Grade 3+ GI toxicities were reported in 0-6% and 0% of patients